Link J S, Bateman J R, Paroly W S, Durkin W J, Peters R L
Cancer. 1977 May;39(5):1936-9. doi: 10.1002/1097-0142(197705)39:5<1936::aid-cncr2820390504>3.0.co;2-n.
Twenty-one patients with biopsy-proven hepatocellular carcinoma were treated with oral or intravenous 5-Fluorouracil according to a randomized treatment schedule. Twenty-one patients were evaluable for response and toxicity. The two groups were comparable in distribution of pretreatment characteristics. There were no objective responses in either group. This is the largest reported group of patients with hepatocellular carcinoma treated with 5-Fluorouracil. Toxicity occurred in 46% of patients treated, but was tolerable. In contrast to previous reports, we have found that weekly 5-Fluorouracil given orally or intravenously is not of significant value in the treatment of hepatocellular carcinoma.
21例经活检证实为肝细胞癌的患者，按照随机治疗方案接受口服或静脉注射5-氟尿嘧啶治疗。21例患者可评估疗效和毒性。两组患者的治疗前特征分布具有可比性。两组均未出现客观缓解。这是报道的接受5-氟尿嘧啶治疗的肝细胞癌患者中最大的一组。46%接受治疗的患者出现毒性反应，但可耐受。与之前的报道相反，我们发现口服或静脉注射每周一次的5-氟尿嘧啶在肝细胞癌治疗中没有显著价值。
